Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$49.29

0.93 (1.92%)

, CTLT

Catalent

$53.26

1 (1.91%)

12:25
12/16/19
12/16
12:25
12/16/19
12:25

Cantor pharma/biotech analysts to hold an analyst/industry conference call

Large Cap & Specialty Pharmaceuticals Analyst Chen and Biotech Analysts Young & Kumar, along with Key Opinion Leader Dr. Nam H. Dang, Professor of Medicine--Hematology/Oncology at the University of Florida, discuss takeaways from the recently-held 61st ASH Annual Meeting for BTK Inhibitors on an Analyst/Industry conference call to be held on December 16 at 1 pm.

AZN

AstraZeneca

$49.29

0.93 (1.92%)

CTLT

Catalent

$53.26

1 (1.91%)

ARQL

ArQule

$20.23

0.16 (0.80%)

TGTX

TG Therapeutics

$9.98

-0.1 (-0.99%)

LLY

Eli Lilly

$122.70

1.16 (0.95%)

  • 16

    Dec

  • 17

    Dec

  • 17

    Dec

  • 30

    Jan

AZN AstraZeneca
$49.29

0.93 (1.92%)

12/02/19
COWN
12/02/19
NO CHANGE
Target $55
COWN
Outperform
AstraZeneca price target raised to $55 from $48 at Cowen
Cowen analyst Steve Scala raised his price target on AstraZeneca to $55 from $48 as he believes its product momentum and high relative growth are not recognized. The analyst believes there is opportunity for upside as forecasts are below the company's guidance and its low relative exposure to the U.S. makes it less vulnerable to election rhetoric. Scala reiterated his Outperform rating on AstraZeneca shares.
12/16/19
STFL
12/16/19
DOWNGRADE
Target $28
STFL
Hold
Stifel 'taking profits' on Amarin following FDA approval, downgrades to Hold
Stifel analyst Derek Archila downgraded Amarin (AMRN) to Hold from Buy with a price target of $28, up from $26, after the FDA approved Vascepa for an expanded indication as an adjunct therapy in patients on statins with high triglycerides who have established CV disease and also for diabetic patients with greater than 2 cardiovascular risk factors. While he said "there is no doubt in our mind Vascepa will be a multi-billion dollar product," Archila prefers to "take profits" at the stock's current valuation near $11B fully diluted. He also points to unpredictability around Vascepa's intellectual property litigation, the drug's "relatively short" exclusivity period, and AstraZeneca's (AZN) Epanova CVOT results next year as downside risks.
12/12/19
HCWC
12/12/19
NO CHANGE
HCWC
Zymeworks may have work-around to AEs of competing drug, says H.C. Wainwright
After AstraZeneca (AZN) and Daiichi Sankyo reported updated clinical data from DS-8201a at the SABCS meeting, H.C. Wainwright analyst Debjit Chattopadhyay said the 14% interstitial lung disease rates are "potentially problematic to physicians" and could limit positioning in earlier lines of therapy despite the drug being "compelling." However, this potential disadvantage is unlikely to be mirrored by Zymeworks' (ZYME) ZW25 and ZW49 for multiple HER2+ breast cancers, contends Chattopadhyay. The analyst keeps a Buy rating on Zymeworks shares.
12/12/19
DBAB
12/12/19
DOWNGRADE
Target $1570
DBAB
Hold
Genmab downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Richard Parkes downgraded Genmab (GMAB) to Hold from Buy with a DKK 1,570 price target. The analyst says the current valuation reflects the company's pipeline. AstraZeneca (AZN) and Roche (RHHBY) are his top large cap picks in European pharmaceuticals due to their "innovation advantage."
CTLT Catalent
$53.26

1 (1.91%)

08/28/19
BARD
08/28/19
NO CHANGE
Target $60
BARD
Outperform
Catalent price target raised to $60 from $50 at Baird
Baird analyst Evan Stover raised his price target on Catalent to $60 from $50 citing recent smaller challenges fading, Paragon and broader Biologics update was solid, and the company is accelerating toward its EBITDA growth goal. Stover reiterated his Outperform rating on Catalent shares.
08/28/19
08/28/19
DOWNGRADE

Sector Weight
Catalent downgraded to Sector Weight on valuation at KeyBanc
As previously reported, KeyBanc analyst Donald Hooker downgraded Catalent to Sector Weight from Overweight on valuation, with shares now at near all-time highs. The analyst believes free cash flow will be limited at 20%-30% of EBITDA due to heavy capital spending, and the company will be carrying a high debt ratio, both of which may limit flexibility.
10/17/19
SPHN
10/17/19
INITIATION
Target $56
SPHN
Overweight
Catalent resumed with an Overweight at Stephens
Stephens analyst Jacob Johnson resumed coverage of Catalent with an Overweight rating and $56 price target. While the stock's valuation is relatively elevated on a historical basis, he thinks the premium is warranted given the growth prospects for the company's biologics and cell/gene therapy assets.
08/28/19
08/28/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Autodesk (ADSK) downgraded to Underperform from Neutral at BofA/Merrill with analyst Kash Rangan saying while the company posted solid July quarter results, uncertainty has increased as its fiscal 2020 guidance was lowered across the board. 2. Antero Midstream (AM) downgraded to Market Perform from Outperform at Raymond James. 3. Catalent (CTLT) downgraded to Sector Weight from Overweight at KeyBanc with analyst Donald Hooker saying he believes free cash flow will be limited at 20%-30% of EBITDA due to heavy capital spending, and the company will be carrying a high debt ratio, both of which may limit flexibility. 4. Kelly Services (KELYA) downgraded to Neutral from Buy at Northcoast with analyst John Healy saying shares are approaching his liquidation value of around $26. 5. Nabors Industries (NBR), Nine Energy Services (NINE), and Quintana Energy Services (QES) downgraded to Neutral from Buy at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ARQL ArQule
$20.23

0.16 (0.80%)

12/10/19
ROTH
12/10/19
DOWNGRADE
Target $18
ROTH
Neutral
ArQule downgraded to Neutral from Buy at Roth Capital
Roth Capital analyst Tony Butler downgraded ArQule (ARQL) to Neutral from Buy with a price target of $18, down from $20, after the company agreed to be acquired by Merck (MRK) for $20 per share in cash for a total equity value of approximately $2.7B. Butler tells investors in a research note that he believes with ArQule's non-covalent BTK inhibitor ARQ 531, Merck may be able to strategically diversify its product portfolio and have an increasing presence in hematologic malignancies.
12/10/19
CANT
12/10/19
DOWNGRADE
Target $20
CANT
Neutral
ArQule downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Varun Kumar downgraded ArQule (ARQL) to Neutral from Overweight with a price target of $20, up from $16. Although other bidders may emerge, the proposed acquisition value paid by Merck (MRK) is fair and makes a "great strategic fit for both parties," Kumar tells investors in a research note.
12/10/19
HCWC
12/10/19
DOWNGRADE
Target $20
HCWC
Neutral
ArQule downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Edward White downgraded ArQule (ARQL) to Neutral from Buy with a price target of $20, up from $13. The analyst cites the proposed takeover by Merck (MRK) for the downgrade.
12/10/19
RBCM
12/10/19
DOWNGRADE
Target $20
RBCM
Sector Perform
ArQule downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital analyst Gregory Renza downgraded ArQule (ARQL) to Sector Perform from Outperform with a $20 price target to reflect the company's agreement to be acquired by Merck (MRK).
TGTX TG Therapeutics
$9.98

-0.1 (-0.99%)

03/29/19
CANT
03/29/19
INITIATION
Target $17
CANT
Overweight
Cantor starts TG Therapeutics with Overweight rating, $17 price target
Cantor Fitzgerald analyst Alethia Young initiated coverage of TG Therapeutics with an Overweight rating and $17 price target. The analyst believes umbralisib and ublituximab have attractive profiles in oncology and autoimmune B-cell diseases. Investors are cautious on the PI3K commercial potential and give no credit to multiple sclerosis due to the competitive yet price sensitive landscape, but both lead assets as clinically de-risked with proven targets, Young tells investors in a research note. She thinks the risk/reward on TG shares is positive.
12/09/19
RILY
12/09/19
NO CHANGE
Target $17
RILY
Buy
TG Therapeutics price target raised to $17 from $12 at B. Riley FBR
B. Riley FBR analyst Mayank Mamtani raised his price target for TG Therapeutics to $17 from $12 citing the company's "solid" Phase I/II triplet data. The data paint a "bright future," says the analyst, who reiterates a Buy rating on TG Therapeutics.
11/27/19
RILY
11/27/19
INITIATION
Target $12
RILY
Buy
TG Therapeutics resumed with a Buy at B. Riley FBR
B. Riley FBR resumed coverage of TG Therapeutics with a Buy rating and $12 price target.
04/12/19
HCWC
04/12/19
NO CHANGE
Target $20
HCWC
Buy
TG granted orphan status for three lymphoma indications, says H.C. Wainwright
The FDA granted TG Therapeutics' umbralisib orphan drug status for three lymphoma indications, H.C. Wainwright analyst Edward White tells investors in a research note. The analyst continues to believe umbralisib will be launched in 2021, generating sales of $10.6M, growing to $141.5M in 2027. He keeps a Buy rating on TG Therapeutics with a $20 price target.
LLY Eli Lilly
$122.70

1.16 (0.95%)

12/16/19
PIPR
12/16/19
NO CHANGE
Target $230
PIPR
Overweight
DexCom pact with Eli Lilly an 'incremental positive,' says Piper Jaffray
Piper Jaffray analyst Matt O'Brien views DexCom's (DXCM) partnership with Eli Lilly (LLY) as an "incremental positive." The timing of the integrated products is uncertain but once available should provide DexCom with another channel for sensor growth, O'Brien tells investors in a research note. Further, the collaboration with such a large player signals the strength of DexCom's continuous glucose monitoring technology, adds the analyst. He believes the partnership "is another barrier that a new entrant will need to hurdle" in order to broadly reach patients across the diabetes market. O'Brien reiterates an Overweight rating on DexCom shares with a $230 price target.
12/16/19
COWN
12/16/19
NO CHANGE
Target $145
COWN
Outperform
Eli Lilly below consensus estimates raised to above consensus at Cowen
Cowen analyst Steve Scala raised his below consensus estimates on Eli Lily to above Street estimates ahead of its 2020 guidance call tomorrow. The analyst said its above average growth should outweigh concerns related to competition to key franchises and pipeline visibility. Scala reiterated his Outperform rating and $145 price target on Eli Lily shares.
10/16/19
BOFA
10/16/19
INITIATION
Target $133
BOFA
Buy
Eli Lilly reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Geoff Meacham reinstated coverage of Eli Lilly with a Buy rating and $133 price target. The analyst sees the company's "high quality, differentiated growth and modest expectations for added pipeline value" as compelling.
11/06/19
LEER
11/06/19
NO CHANGE
LEER
Outperform
ArQule data for ARQ 531 'continue to look strong,' says SVB Leerink
SVB Leerink analyst Jonathan Chang said a "positive update" on the Phase 1 study of ARQ 531 in B-cell malignancies was among the abstracts published ahead of the American Society of Hematology, or ASH, annual meeting. The abstract highlights new partial responses achieved in the "short" window between the European Hematology Association update and the ASH abstract submission deadline, noted Chang, who contends that the data "continue to look strong" for the ArQule (ARQL) drug. The analyst, who also thinks that early data reported by Eli Lilly (LLY) will "intensify investor discussion on the competitive landscape for ARQ 531," still believes ArQule remains in the lead and he reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

SPOT

Spotify

$148.20

-3.59 (-2.37%)

18:15
01/17/20
01/17
18:15
01/17/20
18:15
Periodicals
Spotify in talks to acquire The Ringer, WSJ reports »

Spotify is in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

CE

Celanese

$117.54

-0.53 (-0.45%)

18:00
01/17/20
01/17
18:00
01/17/20
18:00
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

BYND

Beyond Meat

$109.20

-1.16 (-1.05%)

17:58
01/17/20
01/17
17:58
01/17/20
17:58
Periodicals
Beyond Meat rival gets green light in Canada, The Star says »

Impossible Foods, a maker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBD

Diebold

$11.09

-0.49 (-4.23%)

17:42
01/17/20
01/17
17:42
01/17/20
17:42
Periodicals
Breaking Periodicals news story on Diebold »

Diebold Nixdorf divests…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

, SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
General news
Weekly CFTC Commitment of Traders highlights »

2-YEAR U.S. TREASURY net…

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SLV

iShares Silver Trust

$16.82

0.04 (0.24%)

GLD

SPDR Gold Shares

$146.59

0.29 (0.20%)

FXE

Euro Currency Trust

$105.10

-0.43 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBSFY

Ubisoft

$0.00

(0.00%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
Periodicals
Ubisoft to restructure editorial team after difficult 2019, VGC reports »

Ubisoft intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Feb

IMVT

Immunovant

$17.04

-0.01 (-0.06%)

17:27
01/17/20
01/17
17:27
01/17/20
17:27
Syndicate
Breaking Syndicate news story on Immunovant »

Immunovant files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBLT

ToughBuilt

$0.33

-0.0255 (-7.11%)

17:20
01/17/20
01/17
17:20
01/17/20
17:20
Syndicate
ToughBuilt files to sell common stock, no amount given »

Maxim acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYO

Myomo

$0.32

0.0062 (1.98%)

17:18
01/17/20
01/17
17:18
01/17/20
17:18
Conference/Events
Myomo to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRRA

Sierra Oncology

$0.40

-0.02 (-4.76%)

17:14
01/17/20
01/17
17:14
01/17/20
17:14
Conference/Events
Sierra Oncology to host virtual special shareholder meeting »

Virtual Special…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRNE

Sorrento Therapeutics

$4.26

-0.15 (-3.40%)

17:10
01/17/20
01/17
17:10
01/17/20
17:10
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$3.45

-0.1 (-2.82%)

17:01
01/17/20
01/17
17:01
01/17/20
17:01
Hot Stocks
Akers Biosciences reaches settlement agreements on two derivative actions »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECA

Encana

$4.09

-0.18 (-4.22%)

16:40
01/17/20
01/17
16:40
01/17/20
16:40
Hot Stocks
Encana receives court approval for reorganization »

Encana Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

MBRX

Moleculin Biotech

$0.96

0.0122 (1.29%)

16:38
01/17/20
01/17
16:38
01/17/20
16:38
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOD

Vodafone

$20.07

-0.225 (-1.11%)

, BT

BT Group

$0.00

(0.00%)

16:37
01/17/20
01/17
16:37
01/17/20
16:37
Periodicals
BT, Vodafone consider urging PM Johnson not to ban Huawei in U.K., Reuters says »

BT Group (BT) and…

VOD

Vodafone

$20.07

-0.225 (-1.11%)

BT

BT Group

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
01/17/20
01/17
16:30
01/17/20
16:30
Options
Preliminary option volume of 28.7M today »

Preliminary option volume…

NSCO

Nesco Holdings

$5.12

0.025 (0.49%)

16:26
01/17/20
01/17
16:26
01/17/20
16:26
Syndicate
Nesco Holdings requests withdrawal of registration statement »

Nesco Holdings has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$18.54

-0.075 (-0.40%)

, CMCSA

Comcast

$47.48

0.62 (1.32%)

16:20
01/17/20
01/17
16:20
01/17/20
16:20
On The Fly
Fly Intel: Wall Street's top stories for Friday »

The major averages were…

GPS

Gap

$18.54

-0.075 (-0.40%)

CMCSA

Comcast

$47.48

0.62 (1.32%)

CMCSK

Comcast

$0.00

(0.00%)

PLAY

Dave & Buster's

$47.35

5.3 (12.60%)

KKR

KKR

$31.20

0.7 (2.30%)

BA

Boeing

$324.11

-7.89 (-2.38%)

JNJ

Johnson & Johnson

$149.07

0.82 (0.55%)

SWK

Stanley Black & Decker

$172.63

2.18 (1.28%)

TWOU

2U

$22.84

1.05 (4.82%)

BE

Bloom Energy

$9.70

0.43 (4.64%)

MGPI

MGP Ingredients

$38.16

-14.74 (-27.86%)

FAST

Fastenal

$36.77

-0.55 (-1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 20

    Jan

  • 22

    Jan

  • 23

    Jan

  • 29

    Jan

  • 29

    Jan

  • 31

    Jan

  • 26

    Feb

  • 27

    Feb

  • 09

    Mar

  • 17

    Mar

APLS

Apellis

$40.43

0.03 (0.07%)

16:18
01/17/20
01/17
16:18
01/17/20
16:18
Hot Stocks
Apellis CEO sells 30.6K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
01/17/20
01/17
16:17
01/17/20
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
01/17/20
01/17
16:16
01/17/20
16:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:15
01/17/20
01/17
16:15
01/17/20
16:15
General news
Treasury Market Summary »

Treasury Market Summary:…

LGC

Legacy Acquisition Corp

$10.33

(0.00%)

16:08
01/17/20
01/17
16:08
01/17/20
16:08
Hot Stocks
Legacy Acquisition Corp extends date to consummate proposed business combination »

Legacy Acquisition Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNUS

Genius Brands

$0.33

-0.015 (-4.41%)

16:04
01/17/20
01/17
16:04
01/17/20
16:04
Syndicate
Breaking Syndicate news story on Genius Brands »

Genius Brands files $50M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBY

Best Buy

$90.21

1.28 (1.44%)

16:04
01/17/20
01/17
16:04
01/17/20
16:04
Periodicals
Best Buy board opens investigation into CEO's personal conduct, WSJ says »

The board of Best Buy is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.